Albumin-bound Paclitaxel: in metastatic breast cancer.

Abstract:

:A new formulation of paclitaxel, 130-nanometre albumin-bound paclitaxel (nab-paclitaxel), solubilises hydrophobic paclitaxel and may increase paclitaxel delivery to tumour cells. Intravenous nab-paclitaxel 260 mg/m(2) had a higher maximum whole-blood concentration, shorter time to peak concentration, larger distribution volume and greater clearance than a 175 mg/m(2) dose of a conventional polyoxyethylated castor oil (Cremophor EL) solublised paclitaxel (CrEL-paclitaxel). The reconciled target-lesion response rate was significantly higher in patients receiving intravenous nab-paclitaxel 260 mg/m(2) once every 3 weeks than in those receiving CrEL-paclitaxel 175 mg/m(2) once every 3 weeks (21.5% vs 11.1%) in a randomised, nonblind, phase III trial in 454 patients with metastatic breast cancer. The objective response rate (ORR) was also significantly greater in nab-paclitaxel than in CrEL-paclitaxel recipients (33% vs 19%). In noncomparative phase II trials, ORRs of 48% and 51% were observed in patients receiving nab-paclitaxel 175 or 300 mg/m(2) once every 3 weeks. nab-Paclitaxel 260 mg/m(2) caused less grade 4 neutropenia than CrEL-paclitaxel 175 mg/m(2). The incidence of grade 3 sensory neuropathy was higher in nab-paclitaxel recipients, reflecting the higher dosage of nab-paclitaxel, and improved with treatment interruption. Despite the absence of corticosteroid and antihistamine premedication, no severe hypersensitivity reactions were reported.

journal_name

Drugs

journal_title

Drugs

authors

Robinson DM,Keating GM

doi

10.2165/00003495-200666070-00007

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

941-8

issue

7

eissn

0012-6667

issn

1179-1950

pii

6677

journal_volume

66

pub_type

杂志文章

相关文献

DRUGS文献大全
  • Management of patients with advanced non-small cell lung cancer: current and emerging options.

    abstract::Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the last two decades, with modest improvements in quality of life and overall survival. A plateau has been reached with traditional chemotherapy, and efforts are now being directed at developing molecularly targeted agents. To date, thre...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11532200-000000000-00000

    authors: Triano LR,Deshpande H,Gettinger SN

    更新日期:2010-01-01 00:00:00

  • Prescribing oral contraceptives.

    abstract::The combined oral contraceptive pill is the most popular method of contraception worldwide, with modern low-dose formulations significantly improving tolerability. Breakthrough bleeding is the most significant adverse event associated with the low-dose combined oral contraceptives. Monophasic, biphasic, triphasic and ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549020-00007

    authors: Weisberg E

    更新日期:1995-02-01 00:00:00

  • Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.

    abstract::Many drugs alter the anticoagulant effect of oral coumarins. It is essential that physicians be aware of interactions leading to increased or decreased anticoagulation or to erratic control. Interacting drugs can be classified as influencing the pharmacodynamics (pharmacological actions) or the pharmacokinetics (absor...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197611060-00006

    authors: MacLeod SM,Sellers EM

    更新日期:1976-01-01 00:00:00

  • Fidaxomicin: a review of its use in patients with Clostridium difficile infection.

    abstract::Oral fidaxomicin (Dificid(®); Dificlir(®)) is a first-in-class macrocyclic antibacterial that is approved in several countries for the treatment of adult patients with Clostridium difficile-associated diarrhoea. Fidaxomicin 200 mg twice daily for 10 days was an effective and generally well tolerated treatment in adult...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0134-z

    authors: Scott LJ

    更新日期:2013-10-01 00:00:00

  • Emerging options in the treatment of bipolar disorders.

    abstract::Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161100-00004

    authors: Berk M,Segal J,Janet L,Vorster M

    更新日期:2001-01-01 00:00:00

  • Enoxaparin. A review of its clinical potential in the management of coronary artery disease.

    abstract:UNLABELLED:Enoxaparin (enoxaparin sodium) is a low molecular weight heparin (LMWH) that is widely used in the prevention of deep venous thrombosis and pulmonary embolism in patients undergoing orthopaedic or general surgery. Its efficacy in these indications has led to study of its use in patients with coronary artery ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856020-00013

    authors: Noble S,Spencer CM

    更新日期:1998-08-01 00:00:00

  • Danoprevir: First Global Approval.

    abstract::Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0960-0

    authors: Markham A,Keam SJ

    更新日期:2018-08-01 00:00:00

  • Tacrolimus: in patients with rheumatoid arthritis.

    abstract::Tacrolimus, a hydrophobic macrolide with immunosuppressant properties, has recently been evaluated as a new treatment for adults with active rheumatoid arthritis. Oral tacrolimus 3mg once daily was significantly more effective than placebo in patients with rheumatoid arthritis (RA) who were refractory or intolerant to...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565070-00005

    authors: Curran MP,Perry CM

    更新日期:2005-01-01 00:00:00

  • Interaction of lipoproteins with the artery wall.

    abstract::Atherosclerosis can be defined in terms of the processes involved rather than in morphological terms, and there is evidence for possible roles of the macrophage in atherogenesis. The relevance of hyperlipidaemia to the morphogenesis of the atherosclerotic plaque is important, and this has been described in animal mode...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800363-00012

    authors: Woolf N

    更新日期:1988-01-01 00:00:00

  • Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.

    abstract::Anthracyclines are among the most active drugs for the treatment of advanced breast cancer. Epirubicin has been found to be as effective as doxorubicin at equimolar doses but significantly better tolerated, especially in terms of alopecia, leucopenia, and cardiac toxicity. The role of anthracycline-containing regimens...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199300452-00007

    authors: Fumoleau P,Devaux Y,Vo Van ML,Kerbrat P,Fargeot P,Schraub S,Mihura J,Namer M,Mercier M

    更新日期:1993-01-01 00:00:00

  • Mammalian cell-derived somatropin : a review of its use in the management of HIV-associated wasting.

    abstract::HIV-associated wasting, characterised by progressive loss of lean body mass and bodyweight, remains a significant problem in the era of highly active antiretroviral therapy (HAART). Loss of body cell mass, a component of lean body mass, is associated with decreased survival. Somatropin (recombinant human growth hormon...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666030-00014

    authors: Goldsmith DR,Wagstaff AJ

    更新日期:2006-01-01 00:00:00

  • Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.

    abstract::Gene rearrangements involving the neurotrophic receptor kinase genes NTRK1, NTRK2, and NTRK3 (referred to as TRK, encoding TRKA, TRKB, and TRKC, respectively) result in highly oncogenic fusions. TRK fusions are rare, with a prevalence of < 1% in solid tumors. Detection of TRK fusions can be based on fluorescence in-si...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01459-w

    authors: Rohrberg KS,Lassen U

    更新日期:2021-01-05 00:00:00

  • Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

    abstract::Nizatidine is an H2-receptor antagonist which in animal studies was more active on a weight-for-weight basis than cimetidine in inhibiting basal and stimulated gastric acid secretion. Similarly, studies in humans have confirmed that nizatidine is a potent inhibitor of basal, nocturnal and stimulated gastric acid secre...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198836050-00002

    authors: Price AH,Brogden RN

    更新日期:1988-11-01 00:00:00

  • Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.

    abstract::Eplerenone (Inspra) is a selective aldosterone blocker. Oral eplerenone is approved for use in patients with left ventricular (LV) systolic dysfunction and clinical evidence of heart failure following acute myocardial infarction (MI) in the US and in European countries (e.g. the UK and The Netherlands). The addition o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464230-00005

    authors: Keating GM,Plosker GL

    更新日期:2004-01-01 00:00:00

  • Elbasvir/Grazoprevir: First Global Approval.

    abstract::A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0558-3

    authors: Keating GM

    更新日期:2016-04-01 00:00:00

  • Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.

    abstract::Aripiprazole (Abilify®) is an atypical antipsychotic indicated for the treatment of mania associated with bipolar I disorder. It is unique in its class, as it is a partial agonist of dopamine D(2) and D(3), and serotonin 5-HT(1A) receptors and a modest antagonist of 5-HT(2A) receptors. This article reviews the pharmac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208320-000000000-00000

    authors: Dhillon S

    更新日期:2012-01-01 00:00:00

  • Aggravation of ventricular arrhythmia. A drug-induced complication.

    abstract::Each antiarrhythmic agent can cause side effects, but most of these are easily recognised by the patient or physician. However, one potentially serious side effect common to all of these drugs is aggravation of ventricular arrhythmia. Often this is without symptoms and goes unrecognised by the patient. It occurs in 11...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500294-00009

    authors: Podrid PJ

    更新日期:1985-01-01 00:00:00

  • Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

    abstract::The geminal bisphosphonates are a new class of drugs characterised by a P-C-P bond. Consequently, they are analogues of pyrophosphate, but are resistant to chemical and enzymatic hydrolysis. The bisphosphonates bind strongly to hydroxyapatite crystals and inhibit their formation and dissolution. This physicochemical e...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199142060-00003

    authors: Fleisch H

    更新日期:1991-12-01 00:00:00

  • Platelets, thrombosis and drugs.

    abstract::The development of thrombosis involves 4 main factors: the vessel wall, the formed elements of the blood, blood coagulation, and blood flow. In venous thrombosis, however, the major part in both the initiation and growth of thrombi is played by the platelets. In selecting drugs which inhibit platelet function it is he...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197509010-00003

    authors: Mustard JF,Packham MA

    更新日期:1975-01-01 00:00:00

  • Safety profiles of the angiotensin-converting enzyme inhibitors.

    abstract::This review will discuss the safety profiles of the angiotensin-converting enzyme (ACE) inhibitors captopril, enalapril and lisinopril in patients with hypertension. In general, the safety profiles of ACE inhibitors compare favourably with those of other agents used for the treatment of hypertension. Adverse effects a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800355-00016

    authors: Warner NJ,Rush JE

    更新日期:1988-01-01 00:00:00

  • [The kidney as a target organ in diabetic patients with arterial hypertension].

    abstract::Diabetes mellitus has become the most common single cause of end-stage renal disease in the Western world. Diabetic nephropathy, as most forms of renal disease leading to end-stage renal failure, is frequently complicated by arterial hypertension. In type 1 diabetes mellitus the reported excess in arterial hypertensio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Viberti G

    更新日期:2003-01-01 00:00:00

  • Avapritinib: First Approval.

    abstract::Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal tumours (GIST), solid tumours and systemic mastocytosis. Avapr...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01275-2

    authors: Dhillon S

    更新日期:2020-03-01 00:00:00

  • Epidemiological considerations in the treatment of hypertension.

    abstract::Cardiovascular disease continues to be the principal cause of death in Western countries. Epidemiological studies have repeatedly demonstrated a striking relationship between blood pressure and the risk of cardiovascular disease in that those with the highest levels of blood pressure are at the greatest risk for subse...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600314-00003

    authors: Whelton PK,Klag MJ

    更新日期:1986-01-01 00:00:00

  • Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.

    abstract::Although antiangiogenic treatments have produced milestone advances in the treatment of several diseases, and have significantly extended the median survival of cancer patients, these agents share some weaknesses, including a limited impact on the overall cure rate, a fleeting effect because of redundant pathways or e...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0154-8

    authors: Aprile G,Bonotto M,Ongaro E,Pozzo C,Giuliani F

    更新日期:2013-12-01 00:00:00

  • Treatment options for sleep apnoea.

    abstract::Sleep apnoea (SA) is a common sleep disorder affecting 4 to 25% of the adult population. The most common form, obstructive SA, is characterised by recurrent upper airway obstruction during sleep associated with sleep disruption and hypoxaemia. There is increasing evidence that SA leads to impaired vigilance, quality o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161020-00007

    authors: Grunstein RR,Hedner J,Grote L

    更新日期:2001-01-01 00:00:00

  • Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.

    abstract::Cefixime is an orally active third generation cephalosporin with in vitro antibacterial activity against most important lower respiratory pathogens. The drug is active against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae but not Staphylococcus aureus. Cefixime has a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549060-00010

    authors: Markham A,Brogden RN

    更新日期:1995-06-01 00:00:00

  • Treatment of nausea and vomiting in terminally ill cancer patients.

    abstract::Nausea and vomiting is a common and distressing symptom complex in patients with far-advanced cancer, affecting up to 60% of individuals at some stage of their illness. The current approach to the palliative care of patients with nausea and vomiting is based on identifying the cause, understanding its pathophysiology ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/0003495-200868180-00004

    authors: Glare PA,Dunwoodie D,Clark K,Ward A,Yates P,Ryan S,Hardy JR

    更新日期:2008-01-01 00:00:00

  • Treatment of gastroenteritis in children.

    abstract::Mortality and morbidity in gastroenteritis in children is the result of fluid loss, acid-base and electrolyte imbalance. Hence therapy should be aimed at preventing or correcting this imbalance. The use of intestinal antibiotics to treat the condition should not be a routine, but parenteral antibiotic therapy in the p...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197611040-00004

    authors: Tan G

    更新日期:1976-01-01 00:00:00

  • Sickle cell disease in children.

    abstract::Early identification of infants with sickle cell disease (SCD) by newborn screening, now universal in all 50 states in the US, has improved survival, mainly by preventing overwhelming sepsis with the early use of prophylactic penicillin. Routine transcranial Doppler screening with the institution of chronic transfusio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11632890-000000000-00000

    authors: Meier ER,Miller JL

    更新日期:2012-05-07 00:00:00

  • Sorbitol, myo-inositol and sodium-potassium ATPase in diabetic peripheral nerve.

    abstract::Slowing of nerve conduction, a hallmark of both experimental and human diabetic neuropathy, is improved or corrected by aldose reductase inhibitors such as sorbinil. Animal experiments suggest that a myo-inositol-related defect in nerve sodium-potassium adenosine triphosphatase (ATPase) is responsible for the acute re...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198600322-00004

    authors: Greene DA

    更新日期:1986-01-01 00:00:00